Proteasome Treatment may Increase Risk of Cardiovascular Problems
New study carried out by Abramson Cancer Center of the University of Pennsylvania reports that carfilzomib drug can elevate risk of cardiovascular problems in patients suffering from multiple myeloma.
Findings of the study was published in JAMA Oncology journal in December 28, 2017. The proteasome inhibitor drug carfilzomib is used for treatment of multiple myeloma. Analysis of study shows that 18% of multiple myeloma patients receiving carfilzomib experienced cardiovascular adverse events (CVAE) such as hypertension, heart failure, heart attacks or arrhythmia.
More than eight percent of patients experience severe CVAEs more than twice as common as with other drugs for treating relapsed myeloma. According to estimates of American Cancer Society more than 30,200 people were suffering from MM in 2017. Standard treatments for treatment of these include chemotherapy and radiation and status of the patient can be improved with the use of proteasome inhibitors. FDA approved Carfilzomib as proteasome inhibitors, which has functions in breaking down and eliminate proteins inside a cell.
MM requires more proteasomes for survival of patients. The inhibitor drugs block the cells causing the cells to fill up with protein and die. “Like any cancer therapy, the concern with this approach is that it may have an effect on an otherwise healthy part of the body – in this case, the heart,” said the study’s lead author Adam J. Waxman, MD, a Hematology Oncology fellow in the Perelman School of Medicine at the University of Pennsylvania.
Results of the study found that 18.1% of patients taking carfilzomib experienced CVAE, with 8.2% of those cases being grade three or higher. For comparison, a similar review of bortezomib, another proteasome inhibitor found just 3.8% of patients experienced CVAE and only 2.3 percent were severe.
You may be interested
Closed MRI Systems Market – Latest Advancements & Market Outlook 2018 to 2026Pareesh Phulkar - May 21, 2018
Magnetic resonance imaging (MRI) is a non-invasive medical test that uses powerful magnetic field, radio waves, and a computer to produce detailed virtual image of internal organs…
Rising number of surgical procedures coupled with increasing trauma cases to foster global hemostasis & tissue sealing agents marketAlbert R - May 19, 2018
Hemostasis is a physiological processes, which maintains fluidity of blood by preventing blood loss from body. Hemostasis is characterized by clot formation by activating the natural coagulation…
Synovial Sarcoma Treatment Market Regional InsightsAlbert R - May 19, 2018
Synovial sarcoma consists of abnormal growth of soft-tissue. Synovial sarcoma is a rare type of cancer and is more prevalent in teenagers and young adults. Synovial sarcoma…